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Recent experiments have established that Sox9 is required for
chondrocyte differentiation. Here, we show that fibroblast
growth factors (FGFs) markedly enhance Sox9 expression in
mouse primary chondrocytes as well as in C3H10T1y2 cells that
express low levels of Sox9. FGFs also strongly increase the
activity of a Sox9-dependent chondrocyte-specific enhancer in
the gene for collagen type II. Transient transfection experiments
using constructs encoding FGF receptors strongly suggested that
all FGF receptors, FGFR1–R4, can transduce signals that lead to
the increase in Sox9 expression. The increase in Sox9 levels
induced by FGF2 was inhibited by a specific mitogen-activated
protein kinase kinase (MAPKK)ymitogen-activated protein ki-
naseyERK kinase (MEK) inhibitor U0126 in primary chondrocytes.
In addition, coexpression of a dual-specificity phosphatase,
CL100yMKP-1, that is able to dephosphorylate and inactivate
mitogen-activated protein kinases (MAPKs) inhibited the FGF2-
induced increase in activity of the Sox9-dependent enhancer.
Furthermore, coexpression of a constitutively active mutant of
MEK1 increased the activity of the Sox9-dependent enhancer in
primary chondrocytes and C3H10T1y2 cells, mimicking the ef-
fects of FGFs. These results indicate that expression of the gene
for the master chondrogenic factor Sox9 is stimulated by FGFs in
chondrocytes as well as in undifferentiated mesenchymal cells
and strongly suggest that this regulation is mediated by the
MAPK pathway. Because Sox9 is essential for chondrocyte
differentiation, we propose that FGFs and the MAPK pathway
play an important role in chondrogenesis.
Sox9 is a high mobility group DNA-binding domain-containing transcription factor that is expressed in all pre-
chondrocytic and chondrocytic cells during mouse embryonic
development; its expression pattern closely parallels that of the
gene for type II collagen (Col2a1) (1, 2). Recent work from our
laboratory based on mouse embryo chimeras derived from Sox9
homozygous mutant embryonic stem (ES) cells has demon-
strated that Sox9 is a master regulatory factor that is required for
chondrocyte differentiation (3). Indeed, in these chimeras, Sox9
homozygous mutant cells were blocked from differentiating into
chondrocytes; they instead persisted as mesenchymal cells. The
mutant cells were unable to express the genes for chondrocyte-
specific markers, such as collagen types II, IX, and XI and
aggrecan. In addition, no cartilages were formed in teratomas
derived from Sox9 homozygous mutant ES cells. Furthermore,
heterozygous mutations in and around the SOX9 gene in humans
cause campomelic dysplasia (CD), a severe dwarfism syndrome
characterized by anomalies in all skeletal elements derived from
cartilages (4–6). CD is also often associated with XY sex
reversal. In many instances, the disease is thought to be due to
haploinsufficiency, i.e., the remaining 50 percent of SOX9 is
insufficient to perform the physiological function of SOX9.
SOX9 binds to and activates chondrocyte-specific enhancer
elements in the Col2a1 and Col11a2 genes, and ectopic expres-
sion of SOX9 in transgenic mice activates the endogenous
Col2a1 gene, providing evidence that these genes are direct
targets of Sox9 (7–9). SOX9 was recently also shown to regulate
the gene for a cartilage protein CD-RAP (10).
Sox9 expression starts in mesenchymal chondroprogenitor
cells and reaches a high level of expression in differentiated
chondrocytes (1, 2, 11). Sox9 expression is completely down-
regulated in hypertrophic chondrocytes. In addition, Sox9 is
expressed in discrete areas of the urogenital system, brain, and
heart (1, 2, 11, 12).
Fibroblast growth factors (FGF) have important roles in
various processes of embryonic development, including the
earliest stages of limb development. Various FGFs are expressed
in the apical ectodermal ridge during development of vertebrate
limbs, and these ligands in turn regulate the proliferation of the
underlying mesenchyme and outgrowth of the limb bud (13–16).
In addition, at least two FGFs, FGF1 and FGF2, are expressed
in differentiated chondrocytes (17, 18). FGF2 has been shown to
stabilize the phenotype of chondrocytes plated at low density and
to inhibit differentiation of chondrocytes into hypertrophic
chondrocytes in culture (19, 20). Furthermore, intraarticular
administration of FGF2 enhances matrix formation in vivo
(21–23). FGFs signal by binding to a four-member family of
transmembrane tyrosine kinase receptors encoded by Fgfr1,
Fgfr2, Fgfr3, and Fgfr4. During embryonic development, each
FGF receptor displays distinct patterns of expression (24–26).
FGFR1 is the predominant isoform expressed in the mesen-
chyme of the developing limbs, and its expression is maintained
throughout chondrocyte differentiation, including hypertrophic
chondrocytes. Fgfr2 and Fgfr4 are also expressed in cartilage
primordia. In contrast, Fgfr3 expression is restricted to the
resting and proliferating zones of cartilages in the growth plates
(27, 28). It is possible, therefore, that the different receptors play
distinct roles during chondrocyte differentiation. In humans,
mutations in FGFR3 are associated with several forms of
dwarfism, including achondroplasia, thanatophoric dysplasia,
and hypochondroplasia (29–33). Animal models for achondro-
plasia and thanatophoric dysplasia are characterized by a shorter
growth plate, in which proliferation of chondrocytes is markedly
inhibited (28, 34, 35).
We show here that expression of Sox9 is up-regulated by FGF in
primary chondrocytes and in Sox9-expressing mesenchymal cells.
We further present evidence that FGF stimulation of Sox9 expres-
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sion is mediated by the mitogen-activated protein kinase (MAPK)
cascade, a signal transduction pathway that is activated by growth
factors such as FGF. Our data strongly suggest that FGF and the
MAPK pathway play an important role in the regulation of Sox9
expression during chondrocyte differentiation.
Materials and Methods
Reagents. Recombinant FGF1 was prepared as previously de-
scribed (36). Recombinant human FGF2 was from Amersham
Pharmacia. Recombinant FGF7 was either prepared as de-
scribed (37) or purchased from PeproTech (Rocky Hill, NJ).
Recombinant epidermal growth factor (EGF), insulin, and
heparin were from Sigma. Recombinant bone morphogenetic
protein (BMP) 2 and transforming growth factor (TGF)-b1 were
from Genetics Institute (Cambridge, MA) and Life Technolo-
gies (Rockville, MD), respectively. Mitogen-activated protein
kinaseyERK kinase (MEK) inhibitor U0126 was from Promega.
Cell Cultures. Mouse costal chondrocytes were obtained from
1- to 5-day-old mice (38). Prechondrocytic ATDC5 cells were
provided by Tadao Atsumi (The Institute of Physical and
Chemical Research, Tsukuba, Japan) (39). All other cells were
described previously (7, 40, 41). The cells were maintained in
DMEM supplemented with penicillin (50 unitsyml), streptomy-
cin (50 mgyml), L-glutamine (2 mM), and 10% FBS.
RNA Preparation and Northern Blot Analysis. Total cellular RNA
was extracted from cultures by using the TRIZOL Reagent
(Life Technologies). RNA aliquots of 10 mg were loaded on
each lane, fractionated by electrophoresis, and transferred
onto nylon filters (Zeta-Probe GT; Bio-Rad). The filters were
hybridized with 32P-labeled Sox9 and 18S rRNA probes as
described previously (7, 38). Hybridization signals were
quantified by scanning densitometry (Intelligent Quantifier;
BioImage, Ann Arbor, MI).
Western Blot Analysis. Total cellular protein was prepared by
lysing cells in 20 mM TriszHCl (pH 8.0), 150 mM NaCl, 2 mM
EDTA, 1% Triton X-100, 5 mgyml aprotinin, 5 mgyml leupeptin,
5 mgyml pepstatin, and 1 mM PMSF. Protein concentrations
were determined by the Bradford method. Thirty to forty
micrograms of protein was separated by 8% SDSyPAGE
and electrophoretically transferred to nitrocellulose filters
(PROTRAN; Schleicher & Schuell). The filters were blocked in
5% nonfat dry milk in Tris-buffered saline (pH 7.5) containing
0.1% Tween 20 and then incubated with antibodies K-23 (ERK1
and ERK2) or E-4 (Tyr-204 phosphorylated ERK1 and ERK2)
(Santa Cruz Biotechnology) or the Sox9 antibody (8). Filters
were then incubated with the second antibody (horseradish
peroxidase-conjugated anti-rabbit or anti-mouse IgG; Amer-
sham Pharmacia), and the signal was detected by enhanced
chemiluminescence (Amersham Pharmacia).
Plasmids. 4x48-p89 Col2a1 luciferase construction and its MA6
mutant were described previously (41, 42). pcDNA1yNeo (In-
vitrogen) expression vectors encoding FGFR1IIIc, FGFR2IIIc,
FGFR3IIIc, and FGFR4 were either previously described or
generated by subcloning the cDNAs (43–45). pcDNA3.1yZeo
(Invitrogen) expression plasmids encoding the extracellular and
transmembrane domains of FGFR2bIIIb and the kinase do-
mains of FGFR1 or FGFR2 were described previously (46). The
expression plasmid encoding the chimeric FGF receptor con-
sisting of the extracellular and transmembrane domains of
FGFR2bIIIb and the kinase domain of FGFR3 was generated by
ligating the cDNAs at the conserved ApaLI site in the juxtamem-
brane domain and subcloned into pcDNA3.1yZeo. pCS21MT
vectors encoding the wild-type FGFR3IIIc, achondroplasia
(G380R), thanatophoric dysplasia type I (R248C), and type II
(K650E) mutants were generously provided by Michael Naski
and David Ornitz (Washington University School of Medicine,
St. Louis, MO) (47). pFC-MEK1 encoding a constitutively active
mutant of MEK1 (S218y222E, D32–51) was from Stratagene.
pSG5 expression vector (Stratagene) encoding myc-tagged
CL100 was a generous gift from Stephen M. Keyse (Biomedical
Research Centre, Ninewells Hospital, Dundee, U.K.) (48).
pcDNA3 m-Stat1-His-713MyFlag and pcDNA3 m-Stat1-Tyr-
701MyFlag encoding the dominant-negative mutants of Stat1
were kindly provided by Michael J. Walter and Michael J.
Holtzman (Washington University School of Medicine) (49).
Transient Transfections. Cells were transiently transfected with the
reporter constructs by using FuGene6 (Roche Molecular Bio-
chemicals). Briefly, 1.7 ml of Fugene6 was mixed with a total of
600–800 ng of plasmid DNA in 50 ml of standard medium. The
mixture was preincubated for 15 min and added to preestab-
lished monolayers of 3.0 3 105 cells per 4-cm2 well. Cells were
harvested at 24–48 h after transfection. For some of the
experiments, cells were incubated with FGF or other agent for
the last 18–24 h. Reporter plasmids and pSVbgal (Promega),
used as an internal control for transfection efficiency, were
cotransfected in a 3:1 ratio. Luciferase and b-galactosidase
activities were assayed as described previously (40). Promoter
activities were normalized for transfection efficiency and ex-
pressed as fold activity relative to the basal activity of p89, a
construct that harbors the 89-bp minimal Col2a1 promoter but
lacks the 48-bp Col2a1 enhancer.
Results
We first examined the effects of FGF2 on Sox9 mRNA levels in
mouse primary chondrocytes. FGF2 increased the levels of Sox9
mRNA as early as 30 min after addition of FGF2; the increase
lasted for at least 24 h. (Fig. 1A). FGF2 also increased Sox9
protein levels in these cells, which was detected within 90 min
(data not shown, and Fig. 1B), and enhanced the levels of Sox9
protein in the prechondrocytic ATDC5 cells (data not shown).
An increase in Sox9 mRNA and protein was also observed after
treatment of the mesenchymal cell line C3H10T1y2 with FGF2
(data not shown). Both ATDC5 cells and C3H10T1y2 cells
express low levels of Sox9.
We tested other FGFs for their ability to elicit a similar
response, specifically FGF1 and FGF7. Heparin is known to
potentiate the activity of FGF1 in various cell systems (50–52).
FGF1, which binds to all isoforms of FGF receptors, increased
the levels of Sox9 protein in the presence of heparin in primary
chondrocytes (Fig. 1C). In contrast, FGF7 had little or no effect
on Sox9 expression in these cells in the presence or absence of
heparin. FGF7 only binds to a receptor isoform FGFR2IIIb, an
alternatively spliced isoform of FGFR2 selectively expressed in
epithelial cells (50, 53). One possible explanation for the inability
of FGF7 to increase Sox9 expression in chondrocytes would be
that these cells do not express FGFR2IIIb.
To analyze the mechanisms of the regulation of Sox9 expres-
sion by FGFs, we used the activity of a 48-bp Col2a1 enhancer
as a functional measurement of Sox9. In the construct that we
used, four copies of a 48-bp chondrocyte-specific enhancer of the
Col2a1 gene were cloned directly upstream of an 89-bp minimal
Col2a1 promoter (Fig. 2A). The activity of this construct is
entirely dependent on Sox9, and a mutation in the Sox9 binding
site of this enhancer abolishes the activity of this enhancer (7,
42). We first transfected primary chondrocytes with the 4x48-p89
construct and subsequently treated the cells with FGF1, -2, or -7
in the presence or absence of heparin. FGF1 increased the
activity of this enhancer in the presence of heparin in a dose-
dependent manner (Fig. 2B). FGF2 similarly activated this
enhancer, but this activation was not heparin-dependent (Fig.
2C). In contrast, FGF7 did not affect the activity of the enhancer
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(Fig. 2D). A similar pattern of activation of this enhancer was
also observed in C3H10T1y2 cells (Fig. 2E). The activation of
the Sox9-dependent enhancer was specific to FGFs, since insulin,
EGF, TGF-b, and BMP2 did not affect the enhancer activity.
Although BMP2 was reported to enhance Sox9 expression in
other systems (54, 55), we did not observe up-regulation of Sox9
mRNA and protein in these cells (data not shown). The increase
in the activity of the 48-bp Col2a1 enhancer by FGFs paralleled
the increase in Sox9 levels as determined by Western blot
analysis. In addition, both in primary chondrocytes and
C3H10T1y2 cells, FGF2 was unable to activate an identical
construct containing a mutant 48-bp enhancer that abolishes
SOX9 binding and fails to be activated by SOX9 (data not
shown). Furthermore, FGF2 did not activate the 48-bp Col2a1
enhancer in BALBy3T3 fibroblasts and in the osteoblastic
osteosarcoma ROS17y2.8 cells, both of which do not express
Sox9 (data not shown). However, FGF2 activated this enhancer
in ATDC5 cells and the immortalized mouse chondrocyte line
MC615, both of which express Sox9 (data not shown).
We then used the activity of the 48-bp Col2a1 enhancer to
identify FGF receptors that mediated the increase in Sox9
expression produced by FGFs. To bypass the activation of
endogenous FGF receptors, we used vectors expressing chimeric
FGF receptors consisting of the extracellular and transmem-
brane domains of FGFR2bIIIb and the kinase domains of
FGFR1, FGFR2, or FGFR3 (Fig. 3A). Transfections of these
chimeric receptors into primary mouse chondrocytes allowed us
to use FGF7 as ligand, since it requires FGFR2IIIb for binding
(50). The constructs encoding the chimeric FGF receptors were
cotransfected with the 4x48-p89 Col2a1 construct, and the cells
treated with FGF7. Since primary chondrocytes and C3H10T1y2
cells show virtually no response to FGF7, activation of the
enhancer should be because of signaling from the transfected
chimeric FGF receptors. In both cell types, coexpression of
chimeric receptors activated the Sox9-dependent enhancer, and
this activity was further enhanced by FGF7 (Fig. 3B, and data not
shown). Thus, the kinase domains of FGFR1, FGFR2, and
FGFR3 were able to transduce signals that activate the Sox9-
dependent enhancer.
We also tested whether the wild-type FGF receptors
FGFR1IIIc, FGFR2IIIc, FGFR3IIIc, and FGFR4 could further
increase the activation of the Col2a1 enhancer element by FGF2.
The results in Fig. 3C, which presents an experiment performed
in C3H10T1y2 cells, show that coexpression of each of the
wild-type FGF receptors increased the activation of the Sox9-
dependent enhancer by FGF2 alone. These data strongly suggest
that all four FGF receptor tyrosine kinases can transduce signals
that lead to the activation of the Sox9-dependent enhancer
element and imply that a common pathway downstream of the
four FGF receptors is utilized to enhance Sox9 expression.
Because FGFR3IIIc is expressed in resting and proliferating
chondrocytes of growth plates in a pattern that overlaps with the
expression of Sox9 (2, 27, 28) and because activating mutations
of FGFR3 have been implicated in the pathogenesis of chon-
drodysplasias, we examined whether these FGFR3 mutants
activated the Col2a1 enhancer more than the wild-type FGFR3.
Fig. 1. FGFs increase Sox9 mRNA and protein levels in chondrocytes. (A)
Mouse primary chondrocytes were cultured for the indicated periods of time
in the presence or absence of 2 ngyml FGF2. Total RNA was used for Northern
blots to measure Sox9 mRNA levels; an 18S rRNA probe was used as loading
control. FGF2 increased Sox9 mRNA about 3-fold at 24 h. (B) Mouse primary
chondrocytes were cultured for the indicated periods of time in the presence
or absence of 2 ngyml FGF2. Total cell lysates were examined by Western blot
analysis using a Sox9 antibody. FGF2 increased Sox9 protein about 7-fold at
24 h. (C) Mouse primary chondrocytes were treated with 60 ngyml FGF1, 60
ngyml FGF7, or vehicle for 19 h in the presence or absence of 200 mgyml
heparin. The figure presents data from one of two experiments that produced
very similar results.
Fig. 2. FGFs increase the activity of a Sox9-dependent Col2a1 enhancer
construct in chondrocytes and C3H10T1y2 cells. (A) Schematic representation
of a 48-bp chondrocyte-specific Col2a1 enhancer construction and its MA6
mutant. The end points of this enhancer relative to the position of the Col2a1
transcription start site, the Sox9 binding site (underlined segment), and the
mutations in this site (lowercase letters) are indicated. (B–D) Dose-dependent
activation of the enhancer activity by FGFs. Primary chondrocytes were tran-
siently transfected with 4x48-p89 and pSVbgal. FGF1 (B), FGF2 (C), and FGF7
(D) at indicated concentrations were added to the culture medium in the
presence or absence of heparin at 100 mgyml (B and C) or 200 mgyml (D). (E)
FGF-specific activation of the enhancer activity in C3H10T1y2 cells. The cells
were transiently transfected with 4x48-p89 and pSVbgal and treated with
FGF1 (50 ngyml), FGF2 (5 ngyml), FGF7 (10 ngyml), EGF (10 ngyml), insulin (50
mgyml), TGFb (2 ngyml), and BMP2 (100 ngyml). Heparin was added at 100
mgyml. In all panels, promoter activities are average values 6 standard devi-
ations for three independently transfected cultures from one representative
experiment.
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Coexpression of achondroplasia (G380R), thanatophoric dys-
plasia type I (R248C), and type II (K650E) mutants of
FGFR3IIIc each resulted in an increased activity of the Sox9-
dependent enhancer compared with the wild-type receptor in
the absence of ligand. Treatment with FGF1 in combination with
heparin or FGF2 further increased the activity of the enhancer
in cells transfected with the wild-type FGFR3IIIc or its G380R
or K650E mutants. These results are consistent with previous
observations that achondroplasia and thanatophoric dysplasia
mutations are partially activating mutations and that the G380R
and K650E mutants, but not the R248C mutant, retain ligand
dependency (47). These results also suggest the hypothesis that
expression of Sox9 could be regulated by these mutant FGFR3
receptors in achondroplasia and thanatophoric dysplasias.
We then sought to identify the pathway responsible for the
FGF regulation of Sox9 expression. Because the MAPK pathway
has been shown to be activated by FGFs in various cell types
including chondrocytes (56, 57), we first examined the involve-
ment of this pathway using a specific mitogen-activated protein
kinase kinase (MAPKK)yMEK inhibitor, U0126 (58, 59). This
inhibitor exerts its effects at two discrete steps. U0126 inhibits
both the activation of MEK1 and MEK2 by Raf-1 and the
activation of MAPKsyextracellular signal-regulated kinase
(ERK)1 and ERK2 by MEKs. Because serum is a potent
activator of the MAPK cascade, serum concentration was re-
duced to 1% 24 h prior to the experiment. FGF2 increased Sox9
protein levels in parallel with the phosphorylation of ERK1 and
ERK2 in primary chondrocytes (Fig. 4). The MEK inhibitor
U0126 markedly inhibited both the effects of FGF2 on the levels
of Sox9 protein and the phosphorylation of ERK1 and ERK2.
These results support the hypothesis that the increase in Sox9
expression caused by FGF is mediated by the MEK-MAPK
pathway. In a parallel experiment, we examined the time course
of ERK1 and ERK2 phosphorylation after addition of FGF2.
ERK1 and ERK2 were phosphorylated within 5 min after FGF2
treatment in primary chondrocytes, preceding the accumulation
of Sox9 mRNA (data not shown). These data are consistent with
the notion that FGFs may enhance Sox9 mRNA expression
through activation of the MEK-MAPK pathway.
We also examined whether CL100yMAPK phosphatase-1
(MKP-1) can inhibit FGF2 activation of the Sox9-dependent
enhancer in primary chondrocytes. CL100yMKP-1 is a dual-
specificity protein phosphatase that efficiently dephosphorylates
phosphotyrosines and phosphothreonines and inactivates ERK1
and ERK2 (60, 61). Coexpression of CL100yMKP-1 strongly
inhibited the activation of the Sox9-dependent enhancer by
FGF2 (Fig. 5A). This result further supports the hypothesis that
FGF enhances Sox9 expression by means of the MAPK pathway.
Interestingly, coexpression of CL100yMKP-1 remarkably re-
duced the basal activity of the Sox9-dependent enhancer, sug-
gesting that the endogenous level of Sox9 is also regulated by
MAPK in these cells.
Because FGFR3 activates signal transducer and activator of
transcription (STAT)1, we also examined the involvement of
STAT1 in the FGF regulation of the Sox9-dependent enhancer
(57, 62). Either a dominant-negative mutant of STAT1 or
STAT1b, a naturally occurring truncated isoform that inhibits
the activity of full-length STAT1, was cotransfected with 4x48-
p89 in primary chondrocytes (49). Coexpression of these dom-
inant-negative STAT1 constructs did not inhibit the effects of
FGF2 and did not affect the basal activity of the Sox9-dependent
Fig. 3. Activation of a Sox9-dependent Col2a1 enhancer by coexpression of
FGF receptors and FGF treatment. (A) Schematic representation of chimeric
FGF receptors encoding an ectodomain of FGFR2bIIIb and kinase domains of
FGFR1, FGFR2, and FGFR3. FGFR2bIIIb is an alternatively spliced isoform of
FGFR2 that lacks the first Ig-like domain and utilizes IIIb exon for the second
half of the third Ig-like domain. (B) Activation in primary chondrocytes of a
Sox9-dependent Col2a1 enhancer by coexpression of a chimeric FGF receptor
and FGF7 treatment. The cells were transiently transfected with 4x48-p89,
pSVbgal, and 10 ng of the FGFR constructs. FGF7 was added at 20 ngyml. (C)
Activation in C3H10T1y2 cells of a Sox9-dependent Col2a1 enhancer by coex-
pression of FGFR1IIIc, FGFR2IIIc, FGFR3IIIc, and FGFR4 and FGF2 treatment. The
cells were transiently transfected with 4x48-p89, pSVbgal, and 30 ng of the
FGFR constructs. FGF2 was added at 5 ngyml. (D) Activation in primary chon-
drocytes of a Sox9-dependent Col2a1 enhancer by coexpression of wild-type
FGFR3IIIc or its achondroplasia (G380R), thanatophoric dysplasia type I
(R248C), or type II (K650E) mutants in the presence or absence of FGFs. The cells
were transiently transfected with 4x48-p89, pSVbgal, and 100 ng of FGFR3
constructs. FGF1 was added at 60 ngyml in the presence of 100 mgyml heparin.
FGF2 was added at 2 ngyml. In all panels, promoter activities are average
values 6 standard deviations for three independently transfected cultures
from one representative experiment.
Fig. 4. Inhibition by the MEK inhibitor U0126 of FGF2-induced increase in
Sox9 protein and phosphorylation of ERK1 and ERK2 in primary chondrocytes.
Confluent primary chondrocytes were cultured in the presence of 1% FCS for
24 h and incubated with or without 20 mM U0126 for 15 min before addition
of 2 ngyml FGF2 (F) or control vehicle (C). Total cell lysates were prepared 3 h
later and analyzed by Western blot using antibodies that recognize Sox9,
ERK1 and ERK2, and their Tyr 204 phosphorylated forms (p-ERK1, p-ERK2).
FGF2 increased Sox9 protein levels 7-fold in the absence of U0126. U0126
inhibited the increase 85%. The figure represents one of two experiments that
produced very similar results.
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enhancer (data not shown). These results strongly suggest that
FGF regulation of Sox9 is independent of STAT1.
We then tested whether activation of the MEK-MAPK path-
way is sufficient to activate the Sox9-dependent enhancer in
chondrocytes. We cotransfected a constitutively active mutant of
MEK1 with the 4x48-p89 construct. This mutant MEK1 contains
serine-to-glutamic acid substitutions of the two phosphoaccep-
tors at amino acids 218 and 222 in combination with an internal
deletion from amino acid 32 to amino acid 51. These mutations
result in high constitutive activity of MEK1, and the mutant does
not need to be activated by other protein kinases (63, 64).
Coexpression of this mutant MEK1 strongly increased the
activity of the Sox9-dependent enhancer both in primary chon-
drocytes and C3H10T1y2 cells, mimicking the effect of FGFs
(Fig. 5B, and data not shown). Sox9 very likely mediates this
activation, since the constitutively active MEK1 mutant failed to
activate the 48-bp Col2a1 enhancer construct containing a
mutation that abolishes SOX9 binding (Fig. 5C). Furthermore,
the constitutively active MEK1 mutant did not activate the
Sox9-dependent enhancer in osteoblastic osteosarcoma ROS17y
2.8 cells that do not express Sox9 (data not shown). Altogether,
these results strongly suggest that FGFs enhance Sox9 expression
by activating the MEK-MAPK pathway.
Discussion
We have shown that FGFs markedly enhanced expression of
Sox9 in primary chondrocytes. Sox9 mRNA increased within 30
min in these cells, and this increase was reflected in Sox9 protein
levels within 90 min after addition of FGF2. The rapid response
of Sox9 expression after FGF2 treatment strongly suggests that
FGF signaling directly regulates Sox9 expression. FGF2 also
increased Sox9 levels in ATDC5 prechondrocytic cells and in
C3H10T1y2 cells, both of which express low levels of Sox9.
However, in BALBy3T3 fibroblasts that do not express Sox9,
FGF2 was unable to induce Sox9 expression (data not shown).
Despite the increase in Sox9, we did not observe an increase in
Col2a1 mRNA levels in primary chondrocytes and C3H10T1y2
cells (data not shown), maybe because Col2a1 is already maxi-
mally expressed in primary chondrocytes or because an increase
in Col2a1 expression in C3H10T1y2 cells might need additional
factors. Nevertheless, given that Sox9 is essential for chondrocyte
differentiation and for expression of a number of genes in
chondrocytes (3), we hypothesize that FGF signaling may have
an important role in this process.
To explore the pathway by which FGFs increased Sox9
expression in chondrocytes, we used the activity of a 48-bp
Col2a1 enhancer as a functional measurement of Sox9. All four
FGF receptors, FGFR1–4, enhanced the activity of the Sox9-
dependent enhancer, implying that various FGF ligands can
participate in the regulation of Sox9, since multiple ligands can
bind to each of the FGF receptors (50). FGFs could increase the
levels of Sox9 at various steps in the chondrocyte differentiation
pathway, given that FGF receptors are expressed throughout this
pathway. Our findings that activation of FGFR3 increases the
activity of the Sox9-dependent Col2a1 enhancer suggest the
possibility that expression of Sox9 may be regulated by FGFR3
in growth plate chondrocytes. Because we found that achondro-
plasia and thanatophoric dysplasia mutants of FGFR3 activated
the Sox9-dependent enhancer in chondrocytes, it is possible that
Sox9 expression in cartilage is increased in these disorders.
Our study also strongly suggests that the increase in Sox9
expression was mediated by the MEK-MAPK pathway, one of
the major pathways downstream of FGF receptors. Signals from
FGF receptors lead to the activation of MEK, which in turn
phosphorylates and activates MAPKyERK. MAPK then phos-
phorylates and modulates the activity of a variety of kinases and
transcription factors. A specific MEK inhibitor U0126, which
abolished the phosphorylation of ERK1 and ERK2, almost
completely inhibited the increase in Sox9 levels produced by
FGF2. Furthermore, coexpression of a constitutively active
MEK1 mutant strongly increased the activity of the Sox9-
dependent Col2a1 enhancer both in primary chondrocytes and
C3H10T1y2 cells, mimicking the effect of FGFs. In contrast,
cotransfection of a dual-specificity phosphatase, CL100yMKP-1,
that efficiently dephosphorylates and inactivates ERK1 and
ERK2, inhibited the increase in activity of the Sox9-dependent
enhancer in primary chondrocytes. Interestingly, the basal chon-
drocyte-specific activity of the enhancer was strongly inhibited
by CL100yMKP-1 in primary chondrocytes, and a similar inhi-
bition of the basal activity was also observed in the rat chon-
drosarcoma cell line RCS, which stably expresses the chondro-
cyte phenotype (data not shown). This suggests that endogenous
Sox9 levels may be under the control of ERK1 and ERK2 in
chondrocytic cells. The activity of the MAPK pathway has been
implicated in mesoderm induction in Xenopus and in neuronal
differentiation in the PC12 pheochromocytoma cells (65, 66).
Because Sox9 is essential for chondrocyte differentiation and
expression of chondrocyte-specific genes, we hypothesize that
the activity of MAPK plays an important role in chondrocyte
differentiation.
In conclusion, our results demonstrate that FGFs markedly
enhance Sox9 expression both in chondrocytes and Sox9-
expressing mesenchymal and prechondrocytic cells. Our evi-
dence strongly suggests that this FGF-induced increase in Sox9
expression is mediated by the MEK-MAPK pathway. Because
Sox9 is essential for chondrocyte differentiation and expression
of chondrocyte-specific genes, we hypothesize that FGFs and the
activity of the MAPK play an important role in chondrocyte
differentiation.
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Fig. 5. Expression of CL100 or constitutively active MEK1 mutant (S218y222E,
D32–51) modulates the activity of a Sox9-dependent Col2a1 enhancer in
primary chondrocytes. (A) Inhibition of FGF effects on the activity of a Sox9-
dependent Col2a1 enhancer by CL100. Primary chondrocytes were transiently
transfected with 4x48-p89, pSVbgal, and 100 ng of the CL100-expressing or
empty pSG5 vector. Cells were incubated in the presence (1) or absence (2) of
FGF2 at 2 ngyml. (B) Primary chondrocytes were transiently transfected with
4x48-p89, pSVbgal, and 30 ng of pFC-MEK1 or its empty vector. (C) Primary
chondrocytes were transiently transfected with the MA6 mutant of 4x48-p89,
pSVbgal, and 30 ng of pFC-MEK1 or its empty vector. In all panels, promoter
activities are average values 6 standard deviations for three independently
transfected cultures from one representative experiment.
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